SCHEMBL257310

SCHEMBL257310

Cc1cc2[nH]c(=O)cc(-c3cc(F)cc(F)c3)n2n1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.68
RAB9A P51151 1/20 0.68
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP1A2 P05177 2/20 0.40
PARP1 P09874 1/20 0.40
PLAT P00750 5/20 0.40
USP2 O75604 1/20 0.35
TSHR P16473 1/20 0.35
POLB P06746 1/20 0.35
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
ALOX15 P16050 1/20 0.34
SLC11A2 P49281 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL256938 0.87 NPC1 (0.74) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL257697 0.82 NPC1 (0.67) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL257549 0.78 NPC1 (0.74) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL257543 0.77 NPC1 (0.77) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL15020774 0.74 NPC1 (0.60) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL461719 0.74 NPC1 (0.59) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL5461696 0.71 NPC1 (0.56) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL17731131 0.69 PLAT (0.71) NPC1RAB9APLAT
SCHEMBL10072101 0.66 POLB (0.44) NPC1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL3490291 0.65 KCNH2 (0.48) NPC1RAB9AKDM4EPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 NPC1 114/4885RAB9A 542/4885KDM4E 2294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.